Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zongyi Hu

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The Journal of Infectious Diseases|January 27, 2018
Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus InfectionAdam Rolt, Derek Le, Zongyi Hu, et al.
Journal of Medicinal Chemistry|June 29, 2021
Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus AssemblyAdam Rolt, Daniel C Talley, Seung Bum Park, et al.
Journal of Medicinal Chemistry|June 22, 2017
Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication CycleShanshan He, Kelin Li, Billy Lin, et al.
Science Translational Medicine|April 10, 2015
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infectionShanshan He, Billy Lin, Virginia Chu, et al.
ACS Combinatorial Science|September 3, 2015
High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus InhibitorsShanshan He, Prashi Jain, Billy Lin, et al.
Nature Medicine|June 19, 2012
Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunitySebastian Zeissig, Kazumoto Murata, Lindsay Sweet, et al.
Nature Microbiology|September 2, 2020
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusionChristopher D Ma, Michio Imamura, Daniel C Talley, et al.
JCI Insight|December 3, 2024
Repurposing of lonafarnib as a treatment for SARS-CoV-2 infectionMohsin Khan, Parker Irvin, Seung Bum Park, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Journal of Infectious Diseases|January 27, 2018
Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus InfectionAdam Rolt, Derek Le, Zongyi Hu, et al.
Journal of Medicinal Chemistry|June 29, 2021
Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus AssemblyAdam Rolt, Daniel C Talley, Seung Bum Park, et al.
Journal of Medicinal Chemistry|June 22, 2017
Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication CycleShanshan He, Kelin Li, Billy Lin, et al.
Science Translational Medicine|April 10, 2015
Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infectionShanshan He, Billy Lin, Virginia Chu, et al.
ACS Combinatorial Science|September 3, 2015
High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus InhibitorsShanshan He, Prashi Jain, Billy Lin, et al.
Nature Medicine|June 19, 2012
Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunitySebastian Zeissig, Kazumoto Murata, Lindsay Sweet, et al.
Nature Microbiology|September 2, 2020
Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusionChristopher D Ma, Michio Imamura, Daniel C Talley, et al.
JCI Insight|December 3, 2024
Repurposing of lonafarnib as a treatment for SARS-CoV-2 infectionMohsin Khan, Parker Irvin, Seung Bum Park, et al.
Pageof 4